Nizar Tejani, MD
Internal Medicine · Stockbridge, GANPI 1043311459
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 35.9% of the total. 2025 is the largest year on record at $281, 8.8 times the $32 reported in 2019.
Across 20 payments — averaging $39.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$281
- Merck$165
- La Jolla Pharmaceutical Company$131
- Phathom Pharmaceuticals, Inc.$129
- Gilead$30
- Medtronic$18
- plus $29 from 2 others
What the payments were for
- Food & beverage$783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $281 |
| Merck | 6 | $165 |
| La Jolla Pharmaceutical Company | 5 | $131 |
| Phathom Pharmaceuticals, Inc. | 1 | $129 |
| Gilead | 1 | $30 |
| Medtronic | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$783 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 55 | $492 |
| Rosuvastatin Calcium | 64 | $420 |
| Escitalopram Oxalate | 27 | $320 |
| Fluticasone Propionate | 13 | $155 |
| Omeprazole | 16 | $109 |
| Simvastatin | 12 | $109 |
| Metformin Hcl ErMetformin Hcl | 28 | $108 |
| Pantoprazole Sodium | 13 | $78 |
| Amlodipine Besylate | 29 | $77 |
| Montelukast Sodium | 12 | $70 |
| Losartan Potassium | 17 | $61 |
| Metformin Hcl | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Stockbridge
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.